What is the NOAEL for Tafluprost?
Tafluprost has 48 NOAEL studies in the database. The lowest reported value is 1O6WQ6T7G3 UNII. Source: openFDA substances.
NOAEL Data
Cosmetic Ingredient
Tafluprost
CAS 209860-87-7
Tafluprost (CAS 209860-87-7) is a chemical substance. Key regulatory status: 2 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat.
Cross-Vertical Regulatory Divergence
Tafluprost is classified GHS Danger (H302, H319, H360, H370, H372, H413) in the chemicals database but is allowed in EU cosmetics.
SOURCE
Cross-vertical comparison
Cosmetics: ingredients.eu_status; Chemicals: ghs_classifications.signal_word/hazard_statement_code
SOURCE
noael studies public
NOAEL studies
48
SOURCE
chemical inventory jurisdictions
Regulatory lists
2
SOURCE
eu clp annex vi
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
6 fields
Name
Tafluprost
CAS Number
209860-87-7
DTXSID
DTXSID401021504
Molecular Formula
C25H34F2O5
InChI Key
WSNODXPBBALQOF-VEJSHDCNSA-N
Monoisotopic Mass
452.237431
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
1 records
Softener and conditioner
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
2 records
| List | Keyword | Source |
|---|---|---|
| pharmaceutical | US International Trade Commission | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 48 of 48 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 1O6WQ6T7G3 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 1O6WQ6T7G3 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 1O6WQ6T7G3 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 1O6WQ6T7G3 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| >=0.001 | mg/kg bw/day | LEL | injection | Dog | ToxValDB_ECHA_IUCLID |
| >=0.003 | mg/kg bw/day | LEL | injection | Rat | ToxValDB_ECHA_IUCLID |
| >=0.009 | mg/kg bw/day | LEL | injection | Rat | ToxValDB_ECHA_IUCLID |
| >=0.01 | mg/kg bw/day | LEL | injection | Rat | ToxValDB_ECHA_IUCLID |
| =0.03 | mg/kg bw/day | LEL | injection | Rat | ToxValDB_ECHA_IUCLID |
| >=0.15 | ug/eye/time | LEL | oral | Monkey | ToxValDB_ECHA_IUCLID |
| >=0.45 | ug/eye/time | LEL | oral | Monkey | ToxValDB_ECHA_IUCLID |
| =0.0003 | mg/kg bw/day | NOAEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| =0.0003 | mg/kg bw/day | NOAEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| =0.0003 | mg/kg bw/day | NOAEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| =0.0003 | mg/kg bw/day | NOAEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.00001 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.00001 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.00001 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.00001 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.0003 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.0003 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.0003 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.0003 | mg/kg bw/day | NOEL | intravenous | rabbit (New Zealand White; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.01 | mg/kg bw/day | NOEL | injection | Dog | ToxValDB_ECHA_IUCLID |
| <=0.01 | mg/kg bw/day | NOEL | intravenous | dog (Beagle; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.01 | mg/kg bw/day | NOEL | intravenous | dog (Beagle; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.01 | mg/kg bw/day | NOEL | intravenous | dog (Beagle; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.01 | mg/kg bw/day | NOEL | intravenous | dog (Beagle; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.03 | mg/kg bw/day | NOEL | injection | Rat | ToxValDB_ECHA_IUCLID |
| <=0.03 | mg/kg bw/day | NOEL | subcutaneous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.03 | mg/kg bw/day | NOEL | subcutaneous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.03 | mg/kg bw/day | NOEL | subcutaneous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.03 | mg/kg bw/day | NOEL | subcutaneous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.1 | mg/kg bw/day | NOEL | injection | Mouse | ToxValDB_ECHA_IUCLID |
| <=0.1 | mg/kg bw/day | NOEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.1 | mg/kg bw/day | NOEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.1 | mg/kg bw/day | NOEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=0.1 | mg/kg bw/day | NOEL | intravenous | rat (Sprague-Dawley; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=1.35 | ug/eye/time | NOEL | oral | Monkey | ToxValDB_ECHA_IUCLID |
| <=1.35 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=1.35 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=1.35 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=1.35 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=15 | ug/eye/time | NOEL | oral | Monkey | ToxValDB_ECHA_IUCLID |
| <=15 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=15 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=15 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
| <=15 | ug/eye/time | NOEL | other: | monkey (Macaca fascicularis; male/female) | FDA_Toxicity_a881b3e3-f356-4118-b7ee-630b793fd47c_dossier.i6z |
Showing 48 of 48 studies
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
permitted
Max
-
Category
Cosmetic Ingredient
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
EMBL-EBI ChEMBL
TAFLUPROST
ChEMBL Phase
4
Adverse Events
112
Bioactivity
2
Frequently Asked Questions
What regulatory lists include Tafluprost?
Tafluprost appears on 2 regulatory/inventory lists including pharmaceutical, Canada; pharmaceutical. Source: EPA CPDat.
Is Tafluprost used in cosmetics?
Yes, Tafluprost is also indexed as a cosmetic ingredient under the name Tafluprost. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for Tafluprost come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, EPA DSSTox, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Does Tafluprost have different safety status in cosmetics vs industrial chemicals?
Tafluprost is classified GHS Danger (H302, H319, H360, H370, H372, H413) in the chemicals database but is allowed in EU cosmetics.
Is Tafluprost used outside industrial chemicals?
Tafluprost also appears in cosmetics, pharmaceutical databases.